Key result
Dogs with ACVIM stage B2+C MMVD had higher unadjusted median serum aldosterone than stage A+B1, though not significant in multivariable analysis.
Why the study?
Myxomatous mitral valve disease (MMVD) is common in Cavalier King Charles Spaniels (CKCS) and may involve activation of the renin-angiotensin-aldosterone system (RAAS). This study evaluated serum aldosterone concentrations across ACVIM MMVD stages in CKCS and its association with selected echocardiographic indices.
Does serum aldosterone concentration differ across ACVIM stages of myxomatous mitral valve disease and associate with echocardiographic indices in Cavalier King Charles Spaniels?
Cross-Sectional (n=84)
Does serum aldosterone concentration differ across ACVIM stages of myxomatous mitral valve disease and associate with echocardiographic indices in Cavalier King Charles Spaniels?
In Cavalier King Charles Spaniels with myxomatous mitral valve disease, higher serum aldosterone concentrations in advanced stages (B2+C vs. A+B1) were attenuated upon multivariable adjustment and showed no significant associations with echocardiographic indices after correction for multiple testing.
Answers are grounded in this paper and cite their sources.
Unadjusted aldosterone elevation in advanced MMVD stages should not guide therapy; leaves open independent RAAS associations after adjustment in CKCS.
Myxomatous mitral valve disease (MMVD) is common in Cavalier King Charles Spaniels (CKCS) and may involve activation of the renin-angiotensin-aldosterone system (RAAS). This study evaluated serum aldosterone concentrations across ACVIM MMVD stages in CKCS and its association with selected echocardiographic indices. Eighty-four client-owned CKCS were staged according to ACVIM guidelines (A, n = 11; B1, n = 58; B2, n = 7; C, n = 8), and serum aldosterone was measured using the LIAISON® Aldosterone chemiluminescent immunoassay on the DiaSorin LIAISON® XL automated analyzer. In the comparison of serum aldosterone concentrations between the combined ACVIM groups A+B1 and B2+C, the group effect did not reach statistical significance in the multivariable analysis based on complete cases (p = 0.072). In the unadjusted comparison, dogs with ACVIM-defined left-sided cardiac remodeling and/or congestive heart failure (B2+C) had higher median serum aldosterone concentrations than dogs not fulfilling ACVIM criteria for stage B2 or C disease (A+B1) (707.0 [445.0-1150.0] vs. 469.5 [333.5-730.5] pmol/L; p = 0.045), with a moderate rank-biserial effect size (r_rb = 0.332; 95% CI: 0.025-0.612). No significant associations between serum aldosterone concentration and echocardiographic variables remained after false discovery rate (FDR) correction, either in the whole cohort or in the B2+C subgroup. These results suggest a possible difference in serum aldosterone concentrations between broader clinically defined MMVD groups. However, this association was attenuated after multivariable adjustment, and associations with individual echocardiographic indices were not confirmed after correction for multiple testing. The results should therefore be considered preliminary and hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Lewicki et al. (2026) conducted a cross-sectional in Myxomatous mitral valve disease (MMVD) in Cavalier King Charles Spaniels (n=84). ACVIM stage B2 or C myxomatous mitral valve disease (left-sided cardiac remodeling and/or congestive heart failure) vs. ACVIM stage A or B1 myxomatous mitral valve disease was evaluated on Serum aldosterone concentration (pmol/L) (r_rb 0.332, 95% CI 0.025-0.612, p=0.045 (unadjusted); 0.072 (multivariable)). Dogs with ACVIM stage B2+C MMVD had higher unadjusted median serum aldosterone than stage A+B1, though not significant in multivariable analysis.
Synapse has enriched 10 related papers. Consider them for comparative context: